간행물
대한구강악안면병리학회지 KCI 등재 The Korean Journal of Oral and Maxillofacial Pathology
- 발행기관 대한구강악안면병리학회
- 자료유형 학술지
- 간기 격월간
- ISSN 1225-1577 (Print)2384-0900 (Online)
- 수록기간 1977 ~ 2025
- 주제분류 의약학 > 치의학 의약학 분류의 다른 간행물
- 십진분류KDC 515DDC 610
권호리스트/논문검색
제49권 제3호 (2025년 6월) 2건
1.
2025.06
구독 인증기관 무료, 개인회원 유료
The endoplasmic reticulum (ER) is a major storage medium for intracellular calcium (Ca²⁺). Changes in ER Ca²⁺ homeostasis can lead to endoplasmic reticulum stress (ER stress), which, in turn, activates the unfolded protein response (UPR). However, the mechanisms involved remain unclear. This paper investigates the pathways involved in ER stress, ER Ca²⁺ homeostasis, Ca²⁺ channels, and related oral diseases. A systematic search of the literature up to April 8, 2025, was performed using PubMed and Google Scholar with specific terms for ER stress, Ca²⁺ homeostasis, and oral disease. The findings are summarized in both graphical and narrative forms. Disruption of ER Ca²⁺ homeostasis leading to ER stress and UPR can cause cellular dysfunction and inflammation in oral tissues. Understanding the relationship between ER Ca²⁺ homeostasis and ER stress in oral diseases could provide new targets for oral disease treatment.
5,100원
2.
2025.06
구독 인증기관 무료, 개인회원 유료
Oral squamous cell carcinoma (OSCC), which accounts for over 90% of malignancies in the oral cavity, is associated with a poor prognosis, with a 5-year mortality rate reaching of up to 44%. The incidence of OSCC continues to rise annually, and current treatment typically involves a combination of surgical resection, chemotherapy, and radiotherapy. In recent years, there has been growing interest in targeted therapies that exploit molecular markers involved in tumor growth and metastasis. Among these targets, immune checkpoint molecules such as programmed cell death 1 receptor (PD-1) and its ligand, programmed cell death-ligand 1 (PD-L1), have garnered significant attention. Therapies that inhibit these immune checkpoints have been approved for various malignancies, offering new avenues for treatment. Pembrolizumab (Keytruda), a PD-1 immune checkpoint inhibitor, has emerged as a promising therapuetic option for OSCC. However, its clinical response rate in OSCC patients remains below 20%, highlighting the need for combination strategies to enhance therapeutic efficacy. One such approach involves non-thermal plasma (NTP), a novel modality that selectively induces apoptosis in cancer cells. In this study, the authors evaluated the combined effect of Keytruda and NTP in an OSCC xenograft mouse model. The combination therapy demonstrated the tendency of suppressed tumor growth compared to Keytruda monotherapy. This effect was accompanied by increased apoptosis, as indicated by elevated cleaved caspase-3 expression, and reduced proliferation, as shown by decreased Ki-67 expression. Although preliminary, these findings may support the potential clinical application of Keytruda-NTP combined therapy as a novel treatment strategy for OSCC.
4,200원
